Skip to main content

Advertisement

SpringerLink
Log in

Malignant Peritoneal Mesothelioma Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Is GLUT1 Expression a Major Prognostic Factor? A Preliminary Study

  • Gastrointestinal Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

An Erratum to this article was published on 04 January 2014

Abstract

Purpose

Diffuse malignant peritoneal mesothelioma (DMPM) is a rare primary peritoneal malignancy. Its prognosis has been improved by an aggressive locoregional treatment combining extensive cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Prognostic factors are currently poorly defined for this disease but are essential if treatment is to be standardized.

Methods

Twenty-eight patients with DMPM, who were considered preoperatively to be candidates for CRS and HIPEC between June 1998 and August 2010 at our institution, were selected for this study. Medical records and histopathological features were retrospectively reviewed and 24 clinical, histological, and immunohistochemical parameters were assessed for their association with overall survival by univariate and multivariate analyses.

Results

The following factors were significantly associated with overall survival by univariate analysis: predominant histological growth pattern in the epithelioid areas, nuclear grooves in the epithelioid areas, atypical mitoses, and calretinin and GLUT1 expression by immunohistochemistry in the epithelioid areas. Expression of the facilitative glucose transporter protein GLUT1 in the epithelioid areas was the only factor independently associated with overall survival by multivariate analysis.

Conclusions

GLUT1 expression appears to be an indicator of poor prognosis in DMPM. Standard histological classification of DMPM may not be adequate to select patients for aggressive locoregional treatments, such as CRS and HIPEC. Multicenter validation of the prognostic factors identified in this preliminary study is needed to refine patient selection for potential cure.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. Sebbag G, Yan H, Shmookler BM, Chang D, Sugarbaker PH. Results of treatment of 33 patients with peritoneal mesothelioma. Br J Surg. 2000;87:1587-93.

    Article  PubMed  CAS  Google Scholar 

  2. Yan TD, Welch L, Black D, Sugarbaker PH. A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma. Ann Oncol. 2007;18:827-34.

    Article  PubMed  CAS  Google Scholar 

  3. Acherman YI, Welch LS, Bromley CM, Sugarbaker PH. Clinical presentation of peritoneal mesothelioma. Tumori. 2003;89:269-73.

    PubMed  Google Scholar 

  4. Baratti D, Kusamura S, Cabras AD, Laterza B, Balestra MR, Deraco M. Lymph node metastases in diffuse malignant peritoneal mesothelioma. Ann Surg Oncol. 2010;17:45-53.

    Article  PubMed  Google Scholar 

  5. Brigand C, Monneuse O, Mohamed F, Sayag-Beaujard AC, Isaac S, Gilly FN, Glehen O. Peritoneal mesothelioma treated by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy: results of a prospective study. Ann Surg Oncol. 2006;13:405-12.

    Article  PubMed  CAS  Google Scholar 

  6. Deraco M, Nonaka D, Baratti D, et al. Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. Ann Surg Oncol. 2006;13:229-37.

    Article  PubMed  Google Scholar 

  7. Elias D, Bedard V, Bouzid T, Duvillard P, Kohneh-Sharhi N, Raynard B, Goere D. Malignant peritoneal mesothelioma: treatment with maximal cytoreductive surgery plus intraperitoneal chemotherapy. Gastroenterol Clin Biol. 2007;31:784-8.

    Article  PubMed  Google Scholar 

  8. Feldman AL, Libutti SK, Pingpank JF, et al. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol. 2003;21:4560-7.

    Article  PubMed  CAS  Google Scholar 

  9. Hesdorffer ME, Chabot JA, Keohan ML, et al. Combined resection, intraperitoneal chemotherapy, and whole abdominal radiation for the treatment of malignant peritoneal mesothelioma. Am J Clin Oncol. 2008;31:49-54.

    Article  PubMed  CAS  Google Scholar 

  10. Kluger MD, Taub RN, Hesdorffer M, Jin Z, Chabot JA. Two-stage operative cytoreduction and intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma: operative morbidity and mortality in phase I and II trials. Eur J Surg Oncol. 2010;36:997-1003.

    Article  PubMed  CAS  Google Scholar 

  11. Passot G, Cotte E, Brigand C, Beaujard AC, Isaac S, Gilly FN, Glehen O. Peritoneal mesothelioma: treatment with cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy. J Chir. 2008;145:447-53.

    Article  CAS  Google Scholar 

  12. Sugarbaker PH, Welch LS, Mohamed F, Glehen O. A review of peritoneal mesothelioma at the Washington Cancer Institute. Surg Oncol Clin N Am. 2003;12:605-21.

    Google Scholar 

  13. Yan TD, Popa E, Brun EA, Cerruto CA, Sugarbaker PH. Sex difference in diffuse malignant peritoneal mesothelioma. Br J Surg. 2006;93:1536-42.

    Article  PubMed  CAS  Google Scholar 

  14. Yan TD, Yoo D, Sugarbaker PH. Significance of lymph node metastasis in patients with diffuse malignant peritoneal mesothelioma. Eur J Surg Oncol. 2006;32:948-53.

    Article  PubMed  CAS  Google Scholar 

  15. Blackham AU, Shen P, Stewart JH, Russell GB, Levine EA. Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for malignant peritoneal mesothelioma: mitomycin versus cisplatin. Ann Surg Oncol. 2010;17:2720-7.

    Article  PubMed  Google Scholar 

  16. Chua TC, Yan TD, Morris DL. Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: the Australian experience. J Surg Oncol. 2009;99:109-13.

    Article  PubMed  Google Scholar 

  17. Chua TC, Yao P, Akther J, Morris DL. Impact of tumor angiogenesis in peritoneal mesothelioma after radical cytoreduction and hyperthermic intraperitoneal chemotherapy. Pathol Oncol Res. 2010;16:217-22.

    Article  PubMed  Google Scholar 

  18. Loggie BW, Fleming RA, McQuellon RP, Russell GB, Geisinger KR, Levine EA. Prospective trial for the treatment of malignant peritoneal mesothelioma. Am Surg. 2001;67:999-1003.

    PubMed  CAS  Google Scholar 

  19. Yan TD, Deraco M, Baratti D, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol. 2009;27:6237-42.

    Article  PubMed  Google Scholar 

  20. Yan TD, Deraco M, Elias D, et al. A novel tumor-node-metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi-institutional database. Cancer. 2011;117:1855-63.

    Article  PubMed  Google Scholar 

  21. Yan TD, Edwards G, Alderman R, Marquardt CE, Sugarbaker PH. Morbidity and mortality assessment of cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma: a prospective study of 70 consecutive cases. Ann Surg Oncol. 2007;14:515-25.

    Article  PubMed  Google Scholar 

  22. Baratti D, Kusamura S, Cabras AD, Dileo P, Laterza B, Deraco M. Diffuse malignant peritoneal mesothelioma: failure analysis following cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol. 2009;16:463-72.

    Article  PubMed  CAS  Google Scholar 

  23. Borczuk AC, Taub RN, Hesdorffer M, et al. P16 loss and mitotic activity predict poor survival in patients with peritoneal malignant mesothelioma. Clin Cancer Res. 2005;11:3303-8.

    Article  PubMed  CAS  Google Scholar 

  24. Cerruto CA, Brun EA, Chang D, Sugarbaker PH. Prognostic significance of histomorphologic parameters in diffuse malignant peritoneal mesothelioma. Arch Pathol Lab Med. 2006;130:1654-61.

    PubMed  Google Scholar 

  25. Nonaka D, Kusamura S, Baratti D, et al. Diffuse malignant mesothelioma of the peritoneum: a clinicopathological study of 35 patients treated locoregionally at a single institution. Cancer. 2005;104:2181-8.

    Article  PubMed  Google Scholar 

  26. Krasinskas AM, Bartlett DL, Cieply K, Dacic S. CDKN2A and MTAP deletions in peritoneal mesotheliomas are correlated with loss of p16 protein expression and poor survival. Mod Pathol. 2010;23:531-8.

    Article  PubMed  CAS  Google Scholar 

  27. Yan TD, Brun EA, Cerruto CA, Haveric N, Chang D, Sugarbaker PH. Prognostic indicators for patients undergoing cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma. Ann Surg Oncol. 2007;14:41-9.

    Article  PubMed  Google Scholar 

  28. Acurio A, Arif Q, Gattuso P, McIntere M, Krausz T, Husain AN. Value of immunohistochemical markers in differentiating benign from malignant mesothelial lesion. Mod Pathol. 2008;21:334A.

    Article  Google Scholar 

  29. Kato Y, Tsuta K, Seki K, et al. Immunohistochemical detection of GLUT-1 can discriminate between reactive mesothelium and malignant mesothelioma. Mod Pathol. 2007;20:215-20.

    Article  PubMed  CAS  Google Scholar 

  30. Lagana SM, Taub RN, Borczuk AC. Utility of glucose transporter 1 in the distinction of benign and malignant thoracic and abdominal mesothelial lesions. Arch Pathol Lab Med 2012;136:804-9.

    Article  PubMed  Google Scholar 

  31. Monaco SE, Shuai Y, Bansal M, Krasinskas AM, Dacic S. The diagnostic utility of p16 FISH and GLUT-1 immunohistochemical analysis in mesothelial proliferations. Am J Clin Pathol. 2011;135:619-27.

    Article  PubMed  Google Scholar 

  32. Cantuaria G, Fagotti A, Ferrandina G, et al. GLUT-1 expression in ovarian carcinoma: association with survival and response to chemotherapy. Cancer. 2001;92:1144-50.

    Article  PubMed  CAS  Google Scholar 

  33. Fenske W, Volker HU, Adam P, et al. Glucose transporter GLUT1 expression is an stage-independent predictor of clinical outcome in adrenocortical carcinoma. Endocr Relat Cancer. 2009;16:919-28.

    Article  PubMed  Google Scholar 

  34. Haber RS, Rathan A, Weiser KR, et al. GLUT1 glucose transporter expression in colorectal carcinoma: a marker for poor prognosis. Cancer. 1998;83:34-40.

    Article  PubMed  CAS  Google Scholar 

  35. Kawamura T, Kusakabe T, Sugino T, et al. Expression of glucose transporter-1 in human gastric carcinoma: association with tumor aggressiveness, metastasis, and patient survival. Cancer. 2001;92:634-41.

    Article  PubMed  CAS  Google Scholar 

  36. Legan M, Tevzic S, Tolar A, Luzar B, Marolt VF. Glucose transporter-1 (GLUT-1) immunoreactivity in benign, premalignant and malignant lesions of the gallbladder. Pathol Oncol Res. 2011;17:61-6.

    Article  PubMed  CAS  Google Scholar 

  37. Mori Y, Tsukinoki K, Yasuda M, Miyazawa M, Kaneko A, Watanabe Y. Glucose transporter type 1 expression are associated with poor prognosis in patients with salivary gland tumors. Oral Oncol. 2007;43:563-9.

    Article  PubMed  CAS  Google Scholar 

  38. Ozbudak IH, Shilo K, Tavora F, et al. Glucose transporter-1 in pulmonary neuroendocrine carcinomas: expression and survival analysis. Mod Pathol. 2009;22:633-8.

    Article  PubMed  CAS  Google Scholar 

  39. Sung JY, Kim GY, Lim SJ, Park YK, Kim YW. Expression of the GLUT1 glucose transporter and p53 in carcinomas of the pancreatobiliary tract. Pathol Res Pract. 2010;206:24-9.

    Article  PubMed  Google Scholar 

  40. Kao SC, Klebe S, Henderson DW, et al. Low calretinin expression and high neutrophil-to-lymphocyte ratio are poor prognostic factors in patients with malignant mesothelioma undergoing extrapleural pneumonectomy. J Thorac Oncol. 2012;6:1923-9.

    Article  Google Scholar 

  41. Kleinberg L, Lie AK, Florenes VA, Nesland JM, Davidson B. Expression of inhibitor-of-apoptosis protein family members in malignant mesothelioma. Hum Pathol. 2007;38:986-94.

    Article  PubMed  CAS  Google Scholar 

  42. Zaffaroni N, Costa A, Pennati M, et al. Survivin is highly expressed and promotes cell survival in malignant peritoneal mesothelioma. Cell Oncol. 2007;29:453-66.

    PubMed  CAS  Google Scholar 

  43. Sugarbaker PH. Peritonectomy procedures. Ann Surg. 1995;221:29-42.

    Article  PubMed  CAS  Google Scholar 

  44. Gilly FN, Carry PY, Sayag AC, et al. Regional chemotherapy (with mitomycin C) and intra-operative hyperthermia for digestive cancers with peritoneal carcinomatosis. Hepatogastroenterology. 1994;41:124-9.

    PubMed  CAS  Google Scholar 

  45. Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359-74.

    Article  PubMed  CAS  Google Scholar 

  46. Travis WD, Brambilla E, Müller-Hermelink HK, Harris CC. World Health Organization Classification of Tumors: pathology and genetics of tumors of the lung, pleura, thymus and heart. 3rd ed. Lyon: IARC Press; 2004.

    Google Scholar 

  47. Benjamini Y, Yekutieli D. The control of the false discovery rate in multiple testing under dependency. Ann Stat. 2001;29:1165-88.

    Article  Google Scholar 

  48. Antman KH, Osteen RT, Klegar KL, Amato DA, Pomfret EA, Larson DA, Corson JM. Early peritoneal mesothelioma: a treatable malignancy. Lancet. 1985;2:977-81.

    Article  PubMed  CAS  Google Scholar 

  49. Kerrigan SA, Turnnir RT, Clement PB, Young RH, Churg A. Diffuse malignant epithelial mesotheliomas of the peritoneum in women: a clinicopathologic study of 25 patients. Cancer. 2002;94:378-85.

    Article  PubMed  Google Scholar 

  50. Macheda ML, Rogers S, Best JD. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol. 2005;202:654-62.

    Article  PubMed  CAS  Google Scholar 

  51. Kaira K, Serizawa M, Koh Y, et al. Relationship between (18)F-FDG uptake on positron emission tomography and molecular biology in malignant pleural mesothelioma. Eur J Cancer. 2012;48:1244-54.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgment

The study was supported by RENAPE (Centre National de Référence des Tumeurs Rares du Péritoine) depending on INCa (Institut National du Cancer) for the purchase of some antibodies. The authors thank Béatrice Bancel and Céline Michaux for their contribution to laboratory technique, the ARCs Laurent Villeneuve, Isabelle Bonnefoy, Peggy Jourdan-Enfer and Emilie Mathiotte for their help with the clinical database, and Christelle Maurice for her contribution to statistical analysis.

Disclosure

The authors indicate no potential conflict of interest.

Author information

Authors and Affiliations

  1. Service de Chirurgie Générale, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Pierre-Bénite, France

    J. Hommell-Fontaine MD, S. Isaac MD, A. Traverse-Glehen MD, PhD & F. Berger MD, PhD

  2. Service d’Anatomie Pathologique, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Pierre-Bénite, France

    G. Passot MD, E. Cotte MD, PhD, F. N. Gilly MD, PhD & O. Glehen MD, PhD

  3. Service d’Oncologie Medicale, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Pierre-Bénite, France

    B. You MD, PhD

  4. Unité de méthodologie en recherche clinique, Hospices Civils de Lyon, Pole IMER, Lyon, France

    E. Decullier PhD

  5. Université Lyon 1, Lyon, France

    J. Hommell-Fontaine MD, G. Passot MD, E. Decullier PhD, A. Traverse-Glehen MD, PhD, E. Cotte MD, PhD, F. N. Gilly MD, PhD, O. Glehen MD, PhD & F. Berger MD, PhD

  6. Equipe d’Accueil Santé—Individu Société, Université de Lyon, Lyon, France

    E. Decullier PhD

  7. Equipe d’Accueil EMR3738 Ciblage thérapeutique en oncologie, Université Lyon 1, Pierre-Bénite, France

    S. Isaac MD, G. Passot MD, E. Cotte MD, PhD, B. You MD, PhD, F. N. Gilly MD, PhD & O. Glehen MD, PhD

  8. National Pseudomyxoma Peritonei Centre, North Hampshire Hospital, Hampshire, UK

    F. Mohamed MD

Authors
  1. J. Hommell-Fontaine MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Isaac MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G. Passot MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E. Decullier PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. Traverse-Glehen MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. E. Cotte MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. B. You MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. F. Mohamed MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. F. N. Gilly MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. O. Glehen MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. F. Berger MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to O. Glehen MD, PhD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hommell-Fontaine, J., Isaac, S., Passot, G. et al. Malignant Peritoneal Mesothelioma Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Is GLUT1 Expression a Major Prognostic Factor? A Preliminary Study. Ann Surg Oncol 20, 3892–3898 (2013). https://doi.org/10.1245/s10434-013-3077-4

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-013-3077-4

Keywords

Search

Navigation